Why Do Immunotherapy Programs Struggle with Reliable PBMCs Supply?

Immunotherapy programs do not struggle with PBMC supply because suppliers are scarce. They struggle because reliable supply requires three separate capabilities (donor pool depth, donor recall, and GMP grade availability) that most suppliers offer only one or two of. Programs that source from a vendor with all three avoid the supply-chain interruption that hits programs at Phase 2 or commercial scale.

The three capabilities that define reliable PBMC supply

Donor pool depth A reliable PBMC supplier maintains enough qualified donors that any given program can run for years without the underlying pool running out. Industry-standard “deep” pools are 500+ qualified donors; the leading suppliers operate 1,000+ pools. Programs sourcing from vendors with 50 or 100 active donors quickly hit donor-recycling problems where the same donors are over-collected and pool diversity narrows. Donor recall Recall is the ability to come back to a specific donor for repeat collections after the first collection. For programs that need longitudinal samples, comparability runs, or scale-up production from a known donor, recall is non-negotiable. Vendors with deep pools but no recall workflow are useful only for one-time sourcing. Vendors with shallow pools but strong recall workflows can serve targeted programs but not large clinical scale-ups. GMP grade availability Some PBMC vendors operate only RUO. Some operate only GMP. The few that operate both typically run separate donor pools, requiring program teams to requalify donors when scaling from preclinical to clinical. The reliability advantage comes from sourcing from a vendor where the same donor pool serves both RUO and GMP under one quality system.

Why most vendors offer only one or two of the three

The structural reason: building all three is expensive and operationally complex. Deep donor pools require a steady donor recruitment program, donor retention infrastructure, and IRB-approved consent at scale. Most vendors that offer this either own apheresis collection facilities (rare) or partner with multiple blood centers (most common). Partnered vendors typically have less control over recall and GMP donor continuity. Recall capability requires donor relationship management, return collection scheduling, and a quality system that tracks donor identity across collections. Most catalog vendors do not maintain this; they take new donors as they come. GMP availability from the same pool as RUO requires the entire donor consent, screening, and qualification workflow to be GMP-compliant from collection. Most vendors qualify donors as either RUO or GMP based on intended use, which fragments the pool. Vendors that operate all three at the same scale are uncommon enough that they are the binding constraint in vendor selection for immunotherapy programs at scale.

What questions surface vendor capability across all three

When evaluating a PBMC vendor for immunotherapy program supply reliability:

• How many qualified donors are in your active pool today? What were those numbers 12 months ago and 24 months ago?
• What percentage of donors in your pool are available for recall? What is your recall completion rate?
• Do you operate apheresis collection in-house or through partners? If partners, how many?
• Are RUO and GMP grades sourced from the same donor pool under one quality system, or from separate pools? If same, how many donors are qualified for both?
• Show me three programs that have scaled from RUO to GMP with you in the last 24 months without donor requalification.